AR and prostate cancer: We have published that a prototypic small-molecule Sigma1 inhibitor, IPAG, can be used to suppress aberrant AR signaling in prostate cancer cells (57), and we also showed that it could induce autophagy in several different cancer cell lines (55, 56).